Skip to main content
. 2019 Jul 10;21(8):1159–1166. doi: 10.1093/europace/euz175

Figure 2.

Figure 2

(A) Relative risks of conversion within 90 min in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation. (B) Relative risks of conversion within 90 min in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: subgrouped according to whether participants received placebo or active drug.